Specifically, in accordance with the data of the studies SURVEYOR, which were announced in the framework of the annual meeting of the American association for the Study of Liver Diseases (AASLD), after 12 weeks of treatment, between 97 and 100% of patients with chronic hepatitis C genotype 1 achieved a long-term virological response. Respectively, patients of genotype 2 achieved long term virologic response rate of 96-100%, while patients with genotype 3 at a rate of 83-94%.
“These results are encouraging and contribute to the advancement of scientific knowledge about the possibility of developing pan-γονοτυπικών options for the treatment of chronic hepatitis C,” said Fred Poordad, M.D., Vice president for Academic and Clinical Affairs the Texas Liver Institute in San Antonio. “These data are a further important step forward in the continuous research to address the uncovered needs of patients and the medical community”.
The SURVEYOR-I SURVEYOR-II is ongoing clinical phase 2 studies to evaluate the safety and efficacy of ABT-493 (inhibitor of the protease NS3/4A) and ABT-530 (an inhibitor of NS5A) with or without ribavirin, for 8 to 12 weeks. These data relate to non-cirrhotic patients with chronic hepatitis C genotype 1, 2 and 3, while in the future scientific conferences will be presented evidence for additional patient populations (genotypes 4-6).
New research therapy for patients with chronic hepatitis C
—